CR20130182A - COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO - Google Patents

COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO

Info

Publication number
CR20130182A
CR20130182A CR20130182A CR20130182A CR20130182A CR 20130182 A CR20130182 A CR 20130182A CR 20130182 A CR20130182 A CR 20130182A CR 20130182 A CR20130182 A CR 20130182A CR 20130182 A CR20130182 A CR 20130182A
Authority
CR
Costa Rica
Prior art keywords
piridin
ilo
compounds
oxazol
oxazol compounds
Prior art date
Application number
CR20130182A
Other languages
English (en)
Inventor
David Andrew Coates
Raymond Gilmour
Jose Alfredo Martin
De La Nava Eva Maria Martin
Original Assignee
Lilly Co Eli
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130182(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Memory Pharm Corp filed Critical Lilly Co Eli
Publication of CR20130182A publication Critical patent/CR20130182A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a compuestos de oxazolo[5,4-b]piridin-5-ilo útiles en el tratamiento de cáncer.
CR20130182A 2010-12-03 2013-04-25 COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO CR20130182A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382329 2010-12-03
US201161439151P 2011-02-03 2011-02-03
PCT/US2011/061099 WO2012074761A1 (en) 2010-12-03 2011-11-17 Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer

Publications (1)

Publication Number Publication Date
CR20130182A true CR20130182A (es) 2013-07-09

Family

ID=46162794

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130182A CR20130182A (es) 2010-12-03 2013-04-25 COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO

Country Status (27)

Country Link
US (1) US8288548B2 (es)
EP (1) EP2646445B1 (es)
JP (1) JP5726321B2 (es)
KR (1) KR101514162B1 (es)
CN (1) CN103221415B (es)
AR (1) AR083868A1 (es)
AU (1) AU2011337033A1 (es)
BR (1) BR112013013282A2 (es)
CA (1) CA2819822C (es)
CL (1) CL2013001518A1 (es)
CO (1) CO6761387A2 (es)
CR (1) CR20130182A (es)
DO (1) DOP2013000116A (es)
EA (1) EA021241B1 (es)
EC (1) ECSP13012653A (es)
ES (1) ES2567271T3 (es)
GT (1) GT201300139A (es)
IL (1) IL226054A0 (es)
MX (1) MX2013006184A (es)
NZ (1) NZ610289A (es)
PE (1) PE20140008A1 (es)
PH (1) PH12013501115A1 (es)
SG (1) SG190680A1 (es)
TW (1) TWI410425B (es)
UA (1) UA109677C2 (es)
WO (1) WO2012074761A1 (es)
ZA (1) ZA201303580B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102279347B1 (ko) 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3663382B2 (ja) 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
AP2002002460A0 (en) * 2001-03-09 2002-06-30 Pfizer Prod Inc Novel benzimidazole anti-inflammatory compounds.
WO2004014900A1 (en) * 2002-08-09 2004-02-19 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
JP2008501696A (ja) 2004-06-04 2008-01-24 アンフォラ ディスカバリー コーポレーション Ａｔｐ利用酵素阻害活性を示すキノリンおよびイソキノリン系化合物、ならびにその組成物および使用
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
TW200911798A (en) * 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use

Also Published As

Publication number Publication date
TWI410425B (zh) 2013-10-01
CA2819822C (en) 2015-07-21
DOP2013000116A (es) 2014-10-31
PH12013501115A1 (en) 2013-07-22
US20120142724A1 (en) 2012-06-07
US8288548B2 (en) 2012-10-16
EA021241B1 (ru) 2015-05-29
CN103221415A (zh) 2013-07-24
AU2011337033A1 (en) 2013-07-18
CL2013001518A1 (es) 2013-11-04
GT201300139A (es) 2014-04-08
TW201300397A (zh) 2013-01-01
NZ610289A (en) 2015-07-31
ZA201303580B (en) 2014-12-23
UA109677C2 (ru) 2015-09-25
CA2819822A1 (en) 2012-06-07
ECSP13012653A (es) 2013-08-30
JP2013544835A (ja) 2013-12-19
CN103221415B (zh) 2015-06-17
MX2013006184A (es) 2013-07-15
CO6761387A2 (es) 2013-09-30
JP5726321B2 (ja) 2015-05-27
KR101514162B1 (ko) 2015-04-21
AR083868A1 (es) 2013-03-27
EA201390620A1 (ru) 2013-10-30
BR112013013282A2 (pt) 2016-09-06
IL226054A0 (en) 2013-06-27
SG190680A1 (en) 2013-07-31
KR20130093140A (ko) 2013-08-21
PE20140008A1 (es) 2014-01-31
ES2567271T3 (es) 2016-04-21
EP2646445A1 (en) 2013-10-09
WO2012074761A1 (en) 2012-06-07
EP2646445B1 (en) 2016-03-16

Similar Documents

Publication Publication Date Title
CR20110046A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
CR20110580A (es) Compuestos vinil indazolilo
CL2016001733A1 (es) Compuestos intermediarios para la preparación de compuestos derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer div. sol. 3415-12.
CR20130539A (es) Triazolopiridinas
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
BRPI1009118A2 (pt) 3h-imidazo[4,5-c] piridina-6-carboxamidas como agentes anti-inflamatórios
AR091837A1 (es) Compuestos para inmunoterapia dirigida
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
AU2012213775A8 (en) 7-azaindole derivatives
CR20110427A (es) Derivados de triazolo [4,3-b] piridazina y sus usos para el cáncer de próstata
NI201100155A (es) Composiciones y métodos para el tratamiento prolongado con aminopiridinas
HUE042978T2 (hu) Antibakteriális ciklopenta[c]pirrol-szubsztituált 3,4-dihidro-1H-[1,8]naftiridon-származékok
CR20130041A (es) ISOXAZOLO[5,4-b]PIRIDINAS HERBICIDAS
UY34349A (es) OCTAHIDROPIRROLO[1,2-a]PIRAZINA SULFONAMIDAS SUSTITUIDAS COMO BLOQUEADORES DE CANALES DE CALCIO
DOP2013000116A (es) COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO
BR112013000941A2 (pt) formulações de 14-epi-análogos de vitamina d
CR20110023A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
NZ609924A (en) Porphyrin treatment of neurodegenerative diseases
CR20130005A (es) Agentes terapéuticos 976
TN2013000231A1 (en) Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer
MX2015001134A (es) Compuestos terapeuticos.
HK1186470A (en) Oxazolo [5, 4 -b]pyridin- 5 -yl compounds and their use for the treatment of cancer
UA41922U (ru) Применение альтана как вещества с противолучевыми свойствами
UA60741U (en) Derivatives of 8-selenoxospiro[3,5,7,11-tetraazatricyclo[7.3.1.02,7]tridec-2-ene-13,4'-cyclohexane]-1,9-dicarbonitriles